Avamis (fluticasone furoate) nasal spray 27.5 mcg/dose 30 doses №1

$15.30

Manufacturer: GreatBritain

Avamis (fluticasone furoate) nasal spray is used for symptomatic treatment of allergic rhinitis. The onset of action is observed 8 hours after the first application.

Category:

Description

Ingredients

active ingredient : fluticasone furoate:

1 dose contains fluticasone furoate 27.5 mcg;

excipients: anhydrous glucose, dispersed cellulose, polysorbate 80, benzalkonium chloride solution, sodium edetate, purified water.

Dosage form

Nasal spray, suspension, dosed.

Basic physical and chemical properties: white, homogeneous suspension of fluticasone furoate.

Pharmacotherapeutic group

Decongestants and other drugs for topical use in diseases of the nasal cavity. Corticosteroids. ATX code R01A D12.

Pharmacodynamics

Fluticasone furoate is a synthetic fluorinated GCS with a very high level of affinity for GCS receptors and a strong anti-inflammatory effect.

Pharmacokinetics

Fluticasone furoate undergoes extensive first pass metabolism and incomplete absorption in the liver and intestines, resulting in very little systemic exposure to the drug. Usually, with intranasal application of 110 mcg 1 time per day, a plasma concentration is reached that cannot be measured (<10 pg / ml). The bioavailability of fluticasone furoate, when applied 880 mcg 3 times a day (total daily dose – 2640 mcg) is 0.5%.

The level of binding of fluticasone furoate with plasma proteins is 99%. The drug is widely distributed, the volume of distribution averages 608 liters.

Fluticasone furoate is rapidly excreted (total clearance – 58 l / h) from the systemic circulation, mainly by hepatic metabolism with the participation of the cytochrome P450 CYP3A4 enzyme to the inactive 17β-carboxylic metabolite (GW694301X). The main mechanism of metabolism is the hydrolysis of S-fluoromethyl carbotinate to the metabolite, 17β-carboxylic acid. It is excreted after oral and intravenous use mainly with feces with signs of excretion of fluticasone furoate and its metabolites in bile. After intravenous administration, the elimination half-life is 15.1 hours. The urinary excretion rate is approximately 1% and 2% after oral and intravenous administration, respectively.

Indications

Symptomatic treatment of allergic rhinitis.

Contraindications

Hypersensitivity to the components of the drug.

Dosage and administration

Avamis (fluticasone furoate) should be prescribed only for intranasal use.

Adults and children over 12 years of age : the recommended initial dose is 2 injections (27.5 mcg per injection) in each nostril 1 time per day (total daily dose is 110 mcg).

After achieving control of the symptoms of rhinitis, the maintenance dose can be reduced to 1 injection in each nostril 1 time per day (total daily dose – 55 mcg).

Children aged 6 to 11 years: The recommended starting dose is 1 spray in each nostril 1 time per day (total daily dose is 55 micrograms).

In case of insufficient control of rhinitis symptoms when injected into each nostril 1 time per day (total daily dose – 55 mcg), the dose can be increased to 2 injections into each nostril 1 time per day (total daily dose – 110 mcg).

After achieving control of rhinitis symptoms, it is recommended to reduce the dose to 1 injection in each nostril 1 time per day (total daily dose – 55 mcg).

Elderly patients use the same doses as for adults.

Renal failure : dose adjustment is not required.

Liver failure: dose adjustment is not required.

To obtain the full therapeutic effect, it is necessary to use Avamis (fluticasone furoate) regularly. The onset of action is observed 8 hours after the first application, however, the maximum therapeutic effect occurs after a few days from the start of treatment, and therefore patients should be informed that the effect of the treatment will be observed with regular use of Avamis (fluticasone furoate). The duration of treatment should be limited to the period of exposure to the allergen.